EastWest Bioscience Pushes Boundaries to Expand Into Cannabis and CBD

Vancouver, British Columbia – Harbour Star Capital Corp. dba Eastwest BioScience Inc (TSXV:EAST) (“Eastwest” or the “Company“), announces it has engaged Phytosciences Consulting LLC. (“Phytosciences”), a US-based consulting firm with an array of cannabis expertise ranging from laboratory design, specification, and setup to pharmaceutical product design, testing, and manufacturing.

Phytosciences provides quality control and quality assurance services to the medical cannabis industry. Phytoscience’s management team consists of experienced cannabis research scientists and extraction specialists. Guided by sound and well-designed clinical research, Phytoscience is focused on developing standardized cannabis-based therapeutics and has been instrumental in developing many of the established standards within the cannabis laboratory testing and product development sector, becoming a global leader in Good Laboratory and Testing Practices for cannabis. Phytoscience clients’ can be confident the products they develop are designed and manufactured to the highest pharmacological standards.

This engagement of Phytosciences as consultant to EastWest will support EastWest’s ambitious strategy to expand its cannabis operations beyond industrial hemp and hemp food products into the medical marijuana and CBD markets. This will open up new business opportunities with the development of profitable new cannabis products. To that end, the Company has begun its application to the Office of Controlled Substances within Health Canada for a cannabis Dealer’s Licence. This will allow the Company to conduct trade of fresh and dried marijuana, cannabis oils, and concentrates, formulate research and development of cannabis products, and orchestrate analytical testing.

The acquisition of a Dealer Licence will enable EastWest to begin cultivating, extracting, testing, importing, exporting, and producing medical cannabis products including concentrated oil and resin products. The Company intends to produce and market these highly profitable products both domestically and internationally. Attaining its Dealer’s Licence advances the Company’s unique seed-to-shelf strategy and is another major step towards the Company’s 360 Market Vision. This mid-term vision includes acquisition and control of both its supply chain and its’ distribution chain and what the Company believes will be its real competitive market advantage. To that effect, the Company will also be announcing in the near future major acquisitions that will literally bake-in its own sales distribution, a major market strategy unique to EastWest.

About EastWest BioScience Group

EastWest Bioscience is a seed-to-sale organization that offers world class manufacturing and premium hemp-based consumer goods. Since it was founded in 2016, EastWest continues to grow as a high-quality producer, manufacturer and distributor of multiple lines of premium hemp products. EastWest is strategically positioned in mainstream consumer markets with wholistic natural products and has developed distribution channels into mainstream stores and markets in Canada. The Company has a Health Canada licensed, GMP (Good Manufacturing Practices) certified manufacturing facility and produces premium brands offering natural products for a preventive care lifestyle. EastWest consumer product lines are divided into four distinct brands: 1) Natural Advancement – natural biopharmaceutical health supplements; 2) Earth’s Menu – all-natural hemp superfoods; 3) Natural Pet Science – pet food and pet supplements; and 4) Chanvre Hemp – all-natural health and beauty products. The organization will continue to focus on ongoing development of innovative, hemp-based consumer products through advanced science with clean, natural ingredients to complement its current product offerings.

ON BEHALF OF THE BOARD OF DIRECTORS EASTWEST BIOSCIENCE GROUP

“Rodney Gelineau”

Co-Founder, Chief Executive Officer and Director

For investor information and inquiries, please contact EastWest Bioscience Corporate Communications and Investor Relations at investors@eastwestscience.com

Toll free: 1-800-409-1930 ext. 200